When Targeted Therapy Stops Working: Resistance, Repeat Biopsies and the Next Options

The pill had become part of the morning routine, tucked beside the coffee cup for nearly two years. Scans had been quiet. Then a routine appointment ended with a sentence nobody wanted: the latest images show a few areas that have grown. The first question that follows is almost always the same. So what happens when targeted therapy stops working?

It is a fair question, and the honest answer has more shape than most people expect. Losing response to a targeted drug is not the end of a plan; it is a fork in one. Oncologists have a fairly structured way of handling this moment, from confirming that the change is real to figuring out exactly how the cancer escaped.

This article walks through that process the way a clinician might explain it across a kitchen table: what resistance actually is, why a second biopsy is so often requested, and which paths tend to open next.

What happens when targeted therapy stops working?

Targeted therapy is a class of cancer medicine designed to interfere with a specific molecule that helps tumor cells grow, rather than attacking all fast-dividing cells the way traditional chemotherapy does. When it works, the cancer shrinks or holds still because its favorite growth signal has been switched off.

When it stops working, the technical word is progression: the cancer is growing again despite treatment. That can show up in three ways. Scans may show that existing spots have enlarged past an agreed threshold, new spots may appear, or a person may develop symptoms such as a cough that returns, pain in a new place, or fatigue that changes character. Sometimes a blood tumor marker rises first, though markers alone rarely settle the question.

Underneath the scan report is a biological story. Cancer is not a single uniform population of cells. Within a tumor there are countless small variations, and a drug that shuts down one pathway applies pressure that favors any cell able to survive without it. Over months, those survivors multiply. Doctors call this acquired resistance, and it is the reason most targeted therapies for advanced cancer control disease for a period rather than permanently, as MedlinePlus and the National Cancer Institute both describe.

What happens next follows a sequence. First, the team confirms that what they are seeing is genuine progression and not a scan artifact, inflammation, or a healing change. Second, they try to learn how the cancer escaped, often with a repeat biopsy. Third, they match that information against available treatments, which may include a newer drug aimed at the same target, a different class of medicine, focused radiation to a single growing area, or a clinical trial. Each step is worth understanding in turn, because each one involves choices the treating team will want to make with you rather than for you.

How targeted therapy works, in plain language

Picture a cancer cell as a factory running on one faulty switch that is stuck in the on position. In many cancers that switch is a mutated protein, for example an altered growth-factor receptor on the cell surface or an overactive enzyme inside the cell. Because the protein never turns off, the cell keeps dividing.

Most oral targeted drugs belong to a group called tyrosine kinase inhibitors. A kinase is an enzyme that passes chemical messages along a chain; the inhibitor sits in the slot where the kinase would normally bind its fuel, so the message stops. Other targeted treatments are antibodies, large molecules given by infusion that latch onto a receptor from the outside and block it or flag the cell for destruction. The National Cancer Institute groups these under the same umbrella because the principle is identical: pick a molecular weak point and hit only that.

Before any of this can happen, the target has to be found. That is why the original tumor sample went to a laboratory for molecular testing, sometimes called biomarker or genomic testing. The lab looked for specific changes in the DNA or protein of the cancer cells. Only when a matching alteration is present does a targeted drug make sense; without the switch, there is nothing for the key to fit.

This precision is the strength of the approach and also its vulnerability. A drug that blocks a single pathway leaves the rest of the cell’s machinery untouched. Chemotherapy is less selective, which is why it tends to cause broader side effects, but that same bluntness means the cancer has fewer easy escape routes. Targeted therapy trades breadth for accuracy. The Cleveland Clinic summary of targeted therapy notes that cancers can become resistant over time, and the mechanics of that escape are the subject of the next section.

Targeted therapy resistance: the main ways a cancer escapes

Resistance is not one event; researchers describe several distinct routes, and the route matters because it points toward what might work next.

The first is a change in the target itself. A new mutation alters the shape of the protein just enough that the drug no longer fits, while the protein still does its job. In one common form of lung cancer driven by an altered growth-factor receptor, a well-known secondary mutation of this kind was the reason later-generation inhibitors were developed to fit the changed pocket. The National Cancer Institute explains this pattern in its overview of targeted therapies.

The second is a bypass pathway. The blocked switch stays blocked, but the cell activates a different signaling route that reaches the same destination. A useful comparison is a closed highway: traffic reroutes onto a parallel road. In this situation, a drug aimed at the original target alone is unlikely to regain control, and combinations that block both routes are an active area of research.

The third is transformation, where cancer cells change their fundamental type. A tumor that began as one histologic subtype can, under drug pressure, take on the features of a more aggressive subtype that never depended on the original target. Only a tissue biopsy can reveal this, because a blood test reads DNA, not cell appearance.

The fourth is a sanctuary problem rather than a genetic one. Some drugs do not cross into the brain or spinal fluid well, so disease can grow there while remaining controlled elsewhere. This is not true resistance at the cellular level; it is a question of drug delivery, and it is often handled differently.

Finally, resistance can be partial. A single lesion may grow while the rest of the disease stays quiet. That scenario, called oligoprogression, has its own section below because it changes the calculus of whether to switch treatment at all.

How doctors confirm the drug has truly stopped working

A single scan report can be misleading, so oncologists build the case for progression from several pieces of evidence before recommending a change.

Imaging comes first. Radiologists compare the current scan with the previous one and with the baseline taken before treatment began, measuring the size of tracked lesions and noting any new ones. Standardized criteria exist for what counts as growth, so a millimeter of variation between two readers is not treated as progression. Because inflammation and scar tissue can also enlarge on a scan, the team may ask for a repeat image after a short interval when the change is small or ambiguous. Mayo Clinic’s overview of cancer treatment describes imaging as the routine way response is monitored.

Symptoms carry weight too. A cough that returns after months of quiet, new pain in a bone, weight loss without a change in appetite, or a new headache can point the team toward areas a scan has not yet covered. Symptoms are not proof on their own, since side effects and unrelated illness can mimic them, but they inform where to look.

Blood tumor markers, proteins some cancers release into the bloodstream, are a third signal. MedlinePlus notes that these markers are used to monitor how well treatment is working, but also that levels can rise for reasons unrelated to cancer, which is why a rising marker prompts investigation rather than an automatic switch.

Only when these lines of evidence agree, or when one is unmistakable, does the conversation move to what happens when targeted therapy stops working. That deliberate pace can feel slow from the patient’s side of the desk. It exists because stopping a drug that is still helping, on the strength of a single uncertain image, would trade a known benefit for an unknown one.

Who usually keeps taking the drug, and who is asked to switch

Progression on a scan does not automatically mean the prescription ends. The decision turns on how much disease is growing, where, and how the person is feeling.

People most often asked to switch are those with widespread progression: several lesions enlarging, new sites appearing, or symptoms that are clearly worsening. In that setting the drug has lost the argument, and continuing it while the cancer advances offers little.

People often asked to stay on the current drug, at least for now, fall into a few groups. The first is oligoprogression, a term for growth confined to one or a small number of spots while the rest of the disease remains controlled. Here the team may treat the growing area locally with focused radiation or occasionally surgery, and continue the targeted drug for the sites it is still holding. The logic is that the escape is local, and removing the escaped cells may restore the balance.

The second group is brain-only progression on a drug with poor brain penetration. Local treatment of the brain lesions, or a switch to a related drug known to cross into the brain better, may be considered rather than abandoning the class altogether.

A third group is people with slow, asymptomatic growth who feel well. Some teams continue the drug beyond progression while planning the next step, because the moment of switching brings its own risks and a person who is stable and comfortable has time to make a considered choice. Whether this applies depends heavily on the cancer type and the pace of change.

None of these categories is a rule. They are patterns oncologists weigh alongside fitness, kidney and liver function, side effects already accumulated, and what the person wants. The National Cancer Institute’s targeted therapy overview is explicit that combination and sequencing strategies are individualized, and that phrase is the honest summary of this stage.

Why a repeat biopsy after progression matters so much

A biopsy is the removal of a small piece of tissue, or a sample of fluid, so that cells can be examined under a microscope and their DNA analyzed. Many people are surprised to be asked for another one when they already had a biopsy at diagnosis. The reason is that the cancer being treated now is not the same population of cells that was sampled then.

Drug pressure selects for survivors, and the survivors carry whatever change let them survive. The original sample cannot show a mutation that did not yet exist, or existed in too few cells to detect. Only fresh material from a growing lesion can reveal the current picture. In practical terms, a repeat biopsy can answer three questions that directly shape the next treatment: has the target changed shape, has a bypass pathway switched on, and has the cell type transformed.

The answer changes the plan. A shape change might open the door to a later-generation inhibitor designed for the altered target. A bypass finding might point toward a combination or a clinical trial testing two blockers together. Transformation to a different subtype usually redirects treatment toward the chemotherapy used for that subtype, because the original targeted drug no longer has a target.

Repeat biopsies are not risk-free. Depending on the site, they can cause bleeding, infection, pain, or, for lung lesions, a small air leak around the lung. Some lesions sit in places that are hard to reach safely, and some people are too unwell for a procedure. When tissue cannot be obtained, a blood-based test may substitute, with the trade-offs described in the next section.

It is entirely reasonable to ask the team what specifically they hope to learn from a second biopsy and how the result would change what they recommend. If the answer is that it would not change anything, that is useful to know too.

Tissue biopsy vs liquid biopsy: what each can and cannot show

A liquid biopsy is a blood test that looks for fragments of tumor DNA shed into the bloodstream, often called circulating tumor DNA. It has become a common first step at progression because it needs only a blood draw. Understanding what it reveals, and what it misses, helps make sense of why teams sometimes order both.

Feature	Tissue biopsy	Liquid biopsy (blood)
What is sampled	Cells from one growing lesion	DNA fragments from all shedding tumor sites
Can detect a changed target	Yes	Yes, if enough DNA is present
Can detect a bypass pathway	Yes	Often, depending on the alteration
Can detect cell-type transformation	Yes, this requires looking at cells	No
Main limitation	Samples only one site; procedural risk	May miss tumors that shed little DNA; a negative result is not conclusive
Invasiveness	Needle, endoscope, or minor surgery	Blood draw
Typical role at progression	Definitive answer, especially if blood test is negative or transformation is suspected	Fast first look; can guide whether tissue is needed

The key asymmetry is that a positive liquid biopsy is generally trusted, while a negative one is not. Some tumors, particularly those confined to the chest or brain, release little DNA into blood. A blank result therefore means the test did not find anything, not that nothing is there. The National Cancer Institute describes this limitation in its material on biomarker testing.

Many teams now run the blood test first, and proceed to tissue when the blood test is uninformative or when a change in cell type is a real possibility. Others go straight to tissue if a lesion is easy and safe to reach. Neither sequence is universally correct; it depends on the cancer, the anatomy, and how urgently a decision is needed.

What the following weeks usually look like

The stretch between hearing the word progression and starting a new plan is often the hardest part, because it feels like nothing is happening. In reality, quite a lot is.

The first days typically involve additional imaging if the initial scan left any doubt, and possibly imaging of areas not yet covered, such as the brain. Bloodwork checks organ function, since the safety of any next treatment depends on kidneys, liver, and bone marrow being in reasonable shape.

Next comes the molecular workup. A blood-based test is usually drawn early because it needs no scheduling beyond a phlebotomy appointment. If a tissue biopsy is planned, it requires coordination between oncology, radiology or endoscopy, and pathology, so it may take longer to arrange. Once samples are collected, laboratory analysis follows; blood tests generally return sooner than tissue analysis, and the team can tell you the expected turnaround at their center rather than a national average, since this varies.

During this window, the current drug may be continued or paused. Continuing is common when the person feels well and the growth is slow, because it maintains whatever control remains. Pausing is more likely when side effects are heavy or when the next treatment cannot overlap safely with the current one.

Many centers present complex cases at a multidisciplinary tumor board, a meeting of oncologists, radiologists, pathologists, surgeons, and radiation specialists who review the images and molecular results together. This adds a few days but tends to produce a plan that has been stress-tested from several angles.

Finally, there is a conversation. Expect the team to lay out what the tests found, which options fit, what each involves, and what they would suggest and why. It helps to bring someone with you and to write questions down beforehand; the questions section later in this article is a starting point. If a clinical trial is on the table, additional screening tests may be needed before enrollment, which extends the timeline slightly but is part of the process rather than a delay in it.

Treatment options after targeted therapy stops working

What comes next depends on what the resistance workup found, the cancer type, prior treatments, and how the person is doing overall. The broad categories are consistent across many cancers, even though the specifics differ sharply.

A second-line targeted drug is the first consideration when the target has changed shape in a way a newer agent can still fit. Several cancer types now have a sequence of inhibitors developed precisely for this purpose, each aimed at resistance patterns that emerged on the one before. Whether such a drug exists for a particular finding is a question for the team, and it changes as research progresses.

Combination approaches pair a targeted drug with another agent to close a bypass route or to hit the cancer from two directions. Some combinations are established in guidelines; many are still being tested and are available mainly within trials.

Chemotherapy remains a mainstay after targeted options are exhausted, and it is often more effective than people expect after years of hearing that targeted therapy is the modern alternative. For cancers that have transformed to a different cell type, chemotherapy appropriate to the new type is frequently the recommended path. The NHS lung cancer treatment overview describes chemotherapy, targeted therapy, and immunotherapy as complementary tools chosen by type and stage rather than in a fixed order.

Immunotherapy, which works by releasing the brakes on the immune system rather than attacking the cancer directly, may be considered depending on the cancer’s characteristics. In some target-driven cancers, evidence for immunotherapy after targeted therapy is weaker than in others, so this is a point on which honest teams will describe what the studies actually show for that specific situation.

Local treatments, chiefly focused radiation, address a single problematic lesion while systemic treatment continues or changes. Clinical trials sit alongside all of these rather than after them; the section on trials explains why they are worth asking about early. The National Cancer Institute’s targeted therapy overview underlines that resistance is expected and that sequencing and combination are the standard response, not a sign that options have run out.

How long can you stay on targeted therapy?

This is one of the most searched questions on the topic, and the truthful answer is that there is no fixed limit. Targeted therapy for advanced cancer is generally continued for as long as it is helping and being tolerated. That could be months; for some people and some targets it stretches into years. The drug is not stopped because a calendar says so.

Three things end a course of targeted therapy. The first is progression, the subject of this article. The second is intolerable side effects that cannot be managed with supportive measures or adjustments the prescriber judges safe. The third is a decision by the person and their team that the balance of benefit and burden has shifted, which is a legitimate reason regardless of what the scans show.

How long control lasts varies enormously by cancer type, by the specific target, by which generation of drug is used, and by individual biology. Published trials report these durations as medians, meaning the midpoint of a wide spread, and those figures belong to the specific population studied. Asking the treating oncologist for the numbers that apply to your cancer and your drug is far more useful than any general figure, because a median from a different cancer can be misleading in either direction.

Two practical points follow. First, staying on a targeted drug long-term means living with its side effects long-term, so reporting them early matters; many can be eased without changing the prescription, and the prescriber is the right person to judge which. Second, regular monitoring continues throughout, typically with scans at intervals the team sets, so that any loss of control is picked up before symptoms force the issue. MedlinePlus notes that targeted therapy is often given continuously in advanced disease for exactly this reason.

If the drug is still working after a long stretch, that is good news, not a countdown. And if it stops, the framework in this article applies whether that happens after six months or six years.

Does targeted therapy improve life expectancy? What the evidence actually shows

People ask this directly and deserve a direct answer, so here is the honest shape of it. Targeted drugs earn approval by showing, in randomized trials, that they delay progression, improve survival, or both, compared with the previous standard for that specific cancer and target. For several cancers, the arrival of targeted therapy changed the typical course of the disease for people whose tumors carry the matching alteration. That is a genuine achievement of the past two decades of oncology and the reason molecular testing is now routine, as the National Cancer Institute overview explains.

Two caveats keep that statement honest. First, the benefit is specific. A drug that transforms outcomes in one cancer with one mutation does nothing for a cancer without that mutation, which is why targeted therapy is never prescribed on hope alone. Second, trial results are averages across groups. They describe what tends to happen, not what will happen to any one person, and individuals fall on both sides of every median.

What about after resistance? The evidence here is more scattered because it depends on what comes next. Where a later-generation drug exists for a specific resistance mutation, trials have compared it with chemotherapy in that exact setting; where it does not, chemotherapy or immunotherapy data from that cancer type apply. The right question to ask the team is not whether targeted therapy improves life expectancy in general, but what the studies show for your cancer, your resistance pattern, and the specific next option being proposed.

This article deliberately avoids quoting survival percentages, because a number pulled from one trial and applied to a different situation misleads more than it informs. Your oncologist has access to the trial that matches your circumstances and can walk through its results with you, including how confident the data are and where they are thin. That conversation is worth requesting explicitly.

Clinical trials as a real option, not a last resort

A clinical trial is a research study that tests a treatment in people under strict oversight, comparing it against the current standard or studying it in a setting where no standard exists. Progression on targeted therapy is one of the most active areas of trial research, because each newly understood resistance mechanism becomes a target for the next drug.

The common misconception is that trials are for when everything else has failed. In practice, many trials specifically enroll people at the moment of first progression, and eligibility often depends on not having had too many prior treatments. Waiting until later can close doors rather than open them. This is why asking about trials early, at the same appointment where next-line options are discussed, is sensible.

Trials in this space typically fall into a few types. Some test a new inhibitor designed for a specific resistance mutation. Some test combinations that block both the original target and a bypass pathway. Others test entirely different approaches, such as antibody-drug conjugates, which link a targeting antibody to a chemotherapy payload so the toxic agent is delivered preferentially to cancer cells. Molecular results from the repeat biopsy are frequently what determines which trials a person qualifies for, which is another reason the biopsy step matters.

Joining a trial involves trade-offs that deserve plain description. Visits are often more frequent, with extra scans and blood draws. The treatment being tested may turn out to be no better than standard care, or to have side effects not yet fully known. Randomized trials may assign a person to the standard arm rather than the experimental one. Against that, participants receive close monitoring and access to approaches not otherwise available, and they contribute to knowledge that shapes treatment for others.

The National Cancer Institute maintains public information about how trials work and how to discuss them with a care team. Whether a trial is right for a given person is a decision that sits with that person and their oncologist, informed by what is available and what matters most to them.

Supportive and palliative care alongside the next treatment

Palliative care is specialized medical care focused on relieving symptoms and stress from a serious illness, delivered alongside active treatment rather than instead of it. Many people flinch at the word because they associate it with the end of life. That association is out of date, and holding onto it deprives people of help they could use right now.

At the moment targeted therapy stops working, palliative care teams can address several things that oncology visits often lack time for: pain that has crept up, breathlessness, nausea, sleep disruption, anxiety about the transition, and the practical strain on family members. Mayo Clinic’s overview of palliative care describes it as appropriate at any stage of a serious illness and appropriate to receive at the same time as treatment intended to control the disease.

There is also a treatment-planning benefit. Symptoms that are well controlled make a person a better candidate for the next therapy, whether that is a new drug, radiation, or a trial. Fatigue, poor appetite, and uncontrolled pain all reduce the reserve needed to tolerate treatment. Addressing them early is not a separate track from fighting the cancer; it is part of being able to.

Supportive care also covers the unglamorous logistics. Social workers can help with work and insurance questions. Dietitians can address weight loss. Physical therapists can help maintain strength during a period when energy is low. Psychological support, whether counseling or peer groups, addresses the very real fear that arrives with a scan showing growth.

Asking for a palliative care referral is not a statement about prognosis. It is a request for a second team whose entire focus is how you feel day to day. Many people who receive it wish they had asked sooner, and there is no reason to wait for someone else to raise it.

What people often get wrong about targeted therapy resistance

Several ideas circulate in waiting rooms and online forums that do not match the evidence, and correcting them removes some unnecessary dread.

The first myth is that resistance means the drug was the wrong choice. It was not. A targeted drug that controlled disease for months or years did exactly what the trials predicted; resistance is the expected biology of a cancer under selective pressure, not a failure of the prescription or of the person taking it. Nobody caused resistance by missing a dose or eating the wrong food.

The second is that once one targeted drug fails, the whole category is finished. Often the opposite is true. The resistance workup frequently identifies a specific escape route that another agent can address. Even when it does not, chemotherapy and immunotherapy remain, and neither is a lesser option in the abstract.

The third is that a repeat biopsy is a formality. It is the single most consequential step in the sequence, because it determines whether a second targeted drug is even relevant. Skipping it, when it can be done safely, means choosing the next treatment partly blind.

The fourth is that a negative blood test rules out a resistance mutation. As covered earlier, some tumors shed too little DNA for the test to read. A blank liquid biopsy is a reason to consider tissue, not a conclusion.

The fifth is that palliative care means giving up. It does not, and Mayo Clinic’s own description of palliative care is explicit on this point.

The sixth is that clinical trials are only for people out of options. Many trials specifically want people at first progression.

The last is that the person should decide alone or that the doctor should. Neither is right. The evidence provides options; the oncologist provides expertise about them; the person provides the priorities that determine which option fits their life. Decisions belong to that partnership, and it is fine to say so out loud if it seems to be drifting one way.

Questions to ask your care team

A good consultation at this stage is a two-way exchange. These questions tend to draw out the information people most need, and writing them down beforehand keeps a stressful appointment on track.

• Is this definitely progression, or could the scan change be something else? Would another scan in a few weeks help clarify it?
• How much of the cancer is growing, and where? Is this a single spot or widespread change?
• Would a repeat biopsy change what you recommend? If so, tissue, blood, or both, and why that order?
• What resistance mechanisms are common in my type of cancer on this drug, and which ones would open up a different targeted option?
• Should I continue the current drug while we wait for results, and what are the reasons for or against?
• What are all the options if the tests show a new targetable change? What are they if they do not?
• Are there clinical trials that enroll people in my exact situation, and would I need to hold off other treatment to remain eligible?
• For the option you are leaning toward, what did the studies actually show for people with my cancer and resistance pattern, and how confident is that evidence?
• What side effects should I expect from the next treatment, and how do they compare with what I have now?
• Would a palliative care referral help with symptoms during this transition?
• How will we know whether the next treatment is working, and how soon will we check?
• If I want time to think, how much time is reasonable before the decision becomes urgent?

It is also worth asking the team to summarize the plan in writing, or to allow a family member to record the discussion, so that details can be revisited calmly afterward. Most clinicians welcome this. The point of the list is not to interrogate anyone; it is to make sure that when a decision is reached, it rests on shared understanding rather than assumptions on either side.

When to call your doctor

Progression is usually detected on scheduled scans, but some changes need attention before the next appointment. Contact the oncology team promptly, using the emergency line they gave you, if any of the following occur.

New or rapidly worsening shortness of breath, chest pain, or coughing up blood need same-day assessment; they can signal disease in the lungs, a blood clot, or fluid around the lung, all of which are treatable when caught early. Severe headache, new confusion, weakness or numbness on one side of the body, difficulty speaking, a seizure, or sudden vision change can indicate involvement of the brain and require urgent evaluation. Severe or new back pain, especially with leg weakness, numbness in the groin area, or loss of bladder or bowel control, can indicate pressure on the spinal cord, which is an emergency.

A fever while on any cancer treatment should be reported immediately, since some treatments lower the body’s ability to fight infection. Persistent vomiting that prevents keeping fluids down, severe diarrhea, yellowing of the skin or eyes, swelling of one leg, or bleeding that does not stop are also reasons to call rather than wait.

Beyond emergencies, tell the team about any symptom that is new, is getting steadily worse, or is interfering with sleep, eating, or daily activity. Pain in a place that did not hurt before, unexplained weight loss, and fatigue that has changed in quality are worth mentioning even when they seem minor, because they help the team decide whether imaging should be brought forward.

When in doubt, call. Oncology teams would far rather hear about a symptom that turns out to be nothing than learn about a significant one at the next scheduled visit. Every decision about what the symptom means and what to do next rests with the clinicians who know your case; this section is a prompt to reach them, not a substitute for their judgment.

Frequently asked questions

How long can you stay on targeted therapy?

There is no fixed limit; targeted therapy for advanced cancer is usually continued for as long as it is controlling the disease and being tolerated. That can mean months or, for some cancers and targets, years. Treatment ends when scans and symptoms show progression, when side effects become unmanageable, or when the person and their team decide the balance has shifted. Your oncologist can share the typical durations reported for your specific cancer and drug.

Can targeted therapy get rid of stage 4 cancer completely?

In most cases, targeted therapy for stage 4 cancer aims to control the disease rather than eliminate it entirely. Many people achieve long stretches of shrinkage or stability, sometimes lasting years, but the cancer typically adapts eventually through resistance. Outcomes vary widely by cancer type and target, so the most useful answer comes from your treating team, who can explain what trials show for your particular situation and what realistic goals look like.

Does targeted therapy improve life expectancy?

For people whose cancer carries the matching molecular alteration, targeted drugs were approved because trials showed they delayed progression, extended survival, or both compared with the previous standard for that cancer. The benefit is specific to the target and does not apply to cancers without it. Trial results are group averages, not individual predictions, so ask your oncologist what the studies show for your cancer, your resistance pattern, and the next option being proposed.

What is the life expectancy after stopping immunotherapy?

There is no single figure, because it depends on why immunotherapy was stopped, how the cancer responded, the cancer type, and what treatment follows. Immunotherapy differs from targeted therapy in that its effects on the immune system can persist after the drug is discontinued, and some people maintain control for a period without it. Your treating team can discuss the evidence for your specific circumstances rather than a general estimate that may not apply.

What causes targeted therapy resistance?

Resistance develops when cancer cells that can survive without the blocked pathway multiply under drug pressure. The main mechanisms are a new mutation that changes the shape of the target so the drug no longer fits, activation of a bypass signaling route that reaches the same destination, transformation of the cancer to a different cell type that never depended on the target, and growth in places such as the brain where the drug penetrates poorly.

Why do I need a repeat biopsy after progression?

A repeat biopsy shows the cancer as it exists now, not as it was at diagnosis. Drug pressure selects for cells carrying whatever change allowed them to escape, and those changes were often absent or undetectable in the original sample. The result can reveal a new mutation a different drug can address, a bypass pathway suited to a combination or trial, or a change in cell type that redirects treatment toward chemotherapy. It directly shapes the next recommendation.

Is a liquid biopsy as good as a tissue biopsy?

It is complementary rather than equivalent. A liquid biopsy detects tumor DNA fragments in blood from all shedding sites and needs only a blood draw, so it is often done first. However, some tumors shed too little DNA to read, so a negative result does not rule out a resistance mutation. It also cannot show whether the cancer has changed cell type, which requires looking at cells under a microscope. Teams frequently use both.

What are the treatment options after targeted therapy stops working?

Options depend on what the resistance workup finds and the cancer type. They may include a later-generation drug designed for a specific resistance mutation, a combination that blocks both the original target and a bypass pathway, chemotherapy, immunotherapy where evidence supports it, focused radiation to a single growing spot while systemic treatment continues, or a clinical trial. The treating team weighs these against fitness, prior treatments, and the person’s own priorities.

Can I keep taking my targeted drug after progression?

Sometimes, yes. When growth is limited to one or a few spots while the rest of the disease remains controlled, teams often treat the growing area locally and continue the drug. When progression is slow and a person feels well, the drug may be continued while the next plan is arranged. Widespread or symptomatic progression usually means switching. This decision always rests with the prescribing oncologist based on your scans and circumstances.

Is immunotherapy available after targeted therapy?

It can be, depending on the cancer type and its characteristics, but the evidence varies. In some cancers driven by a specific mutation, studies have shown weaker responses to immunotherapy after targeted therapy than in cancers without such drivers, and certain sequences carry particular side-effect concerns. This is an area where your oncologist should describe what the data show for your specific cancer rather than a general answer, and the decision sits with that team.

References

• Targeted therapies for cancer, MedlinePlus
• Targeted Therapy, Cleveland Clinic
• Lung cancer treatment, NHS
• Tumor Marker Tests, MedlinePlus

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.